LL-37 5mg. Used to support immune function, antimicrobial defense, inflammation control, and tissue repair. Lab tested, discreetly shipped across Canada.
FormatLyophilized Vial
ConcentrationDependent on reconstitution with BAC water
Pack Size Selected: 5 Pack
Pay with Interac e-Transfer or Crypto
HPLC verified. COA on file for this batch
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
LL-37 is a 37 amino acid cationic antimicrobial peptide and the only known human cathelicidin. A class of host defence peptides that form a critical component of the innate immune system’s first line response to pathogen invasion. iLab Pharma’s formulation supplies 5mg as a lyophilized vial, preserving peptide structural integrity and potency across storage conditions until reconstitution, important for a cationic peptide whose amphipathic helical structure, central to its antimicrobial mechanism, requires careful storage conditions to maintain functional conformation.
LL-37’s antimicrobial mechanism operates through direct membrane disruption. Its cationic charge enables electrostatic attraction to the negatively charged membranes of bacteria, fungi, and enveloped viruses, followed by insertion into and disruption of the pathogen membrane through a carpet or toroidal pore formation model. This direct membrane disruption mechanism produces broad spectrum antimicrobial activity without the target specific receptor binding that characterizes most antibiotic compounds. A mechanistic distinction that has generated significant research interest in studies examining antimicrobial resistance, as membrane disrupting peptides face fundamentally different resistance development pathways than receptor or enzyme targeting antibiotics.
Beyond its antimicrobial activity, LL-37 carries a well documented immunomodulatory research profile that has expanded its research interest considerably beyond innate immune defense. LL-37 acts as a chemokine and cytokine modulator attracting immune cells to infection sites, promoting angiogenesis through VEGF pathway activation, stimulating wound healing through epithelial cell migration and proliferation, and modulating toll like receptor signaling to regulate the magnitude of inflammatory responses. This dual antimicrobial and immunomodulatory profile makes LL-37 a uniquely positioned research compound in studies examining the intersection of innate immunity, wound healing, and inflammatory regulation. Research areas where its status as the sole human cathelicidin gives it a distinct biological significance that synthetic antimicrobial peptides cannot replicate.
iLab Pharma formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s sourcing standards apply uniformly across all manufacturers we carry, and iLab Pharma’s LL-37 meets those standards consistently. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Reconstitute with bacteriostatic water prior to use. Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.
Commonly researched alongside Thymosin Alpha-1 and VIP in comparative innate immune defense and immunomodulatory peptide studies. Browse CSD’s full peptide range for complete sourcing.
LL-37 is a naturally occurring 37-amino acid human host defense peptide produced from the cathelicidin precursor protein hCAP18. It is an important component of innate immunity and is expressed by several immune and epithelial cell types. LL-37 has been extensively studied for antimicrobial activity, immune regulation, inflammatory signaling, wound repair, angiogenesis, and interactions between host tissues and microorganisms. This product contains 5mg of lyophilized LL-37 in a single vial for laboratory research.
LL-37 is primarily investigated in innate immunity and host defense research. Experimental studies have examined its activity against bacteria and other microorganisms, regulation of inflammatory responses, immune-cell recruitment, wound healing, re epithelialization, angiogenesis, and tissue repair signaling. Research also explores LL-37 in dermatology, respiratory biology, infection models, and inflammatory conditions because the peptide is naturally expressed across multiple barrier tissues.
LL-37 is a positively charged amphipathic peptide capable of interacting with negatively charged components of microbial membranes. This interaction can disrupt membrane integrity under experimental conditions. LL-37 also has broader immunomodulatory actions, including effects on immune cell signaling and responses to microbial components, meaning its biological activity extends beyond direct antimicrobial membrane disruption.
LL-37 is produced by epithelial and immune cells at sites where barrier defense and tissue repair are important. Experimental research has linked the peptide with keratinocyte migration, re epithelialization, angiogenesis, immune cell recruitment, and inflammatory signaling. These overlapping functions have made LL-37 an important research target for understanding how antimicrobial defense and tissue regeneration interact during wound healing.
Yes! This batch is HPLC tested to verify LL-37 identity and content accuracy at 5mg per vial. A certificate of analysis is available.
